Cargando…

The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients

Detalles Bibliográficos
Autores principales:	Uprety, Dipesh, Bista, Amir, Vallatharasu, Yazhini, Arjyal, Lubina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989053/ https://www.ncbi.nlm.nih.gov/pubmed/29887733 http://dx.doi.org/10.1177/1179554918779585

Ejemplares similares

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
por: Lashari, Bilal H., et al.
Publicado: (2018)

YouTube as a Source of Information on Cervical Cancer
por: Adhikari, Janak, et al.
Publicado: (2016)

Community health workers in clinical research at the example of a phase IIIb/ IV antimalarial drug trial conducted in five African countries
por: Groger, Mirjam, et al.
Publicado: (2023)

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors
por: Uprety, Dipesh, et al.
Publicado: (2020)

Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer
por: Yang, Lin, et al.
Publicado: (2015)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022)

Glasgow Prognostic Score in Patients Receiving Chemotherapy for Non-small-cell Lung Cancer in Stages IIIb and IV
por: Umihanic, Sefika, et al.
Publicado: (2014)

Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2015)

In vivo evaluation of an innovative synbiotics on stage IIIb-IV chronic kidney disease patients
por: Vacca, Mirco, et al.
Publicado: (2023)

Pathological complete response in an advance stage IIIB non‐small cell lung cancer secondary to neoadjuvant osimertinib targeted therapy: A case report and review of literature
por: Soo, Chun Ian, et al.
Publicado: (2023)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

Surgery for stage IIB–IIIB small cell lung cancer
por: Huang, Zhida, et al.
Publicado: (2023)

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2018)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety, Dipesh
Publicado: (2019)

Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer
por: Gupta, Digant, et al.
Publicado: (2009)

Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer
por: Zhao, Lei, et al.
Publicado: (2017)

The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
por: Wang, Yuan, et al.
Publicado: (2017)

A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib
por: Bhuiyan, Sakil, et al.
Publicado: (2021)

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
por: Nokihara, Hiroshi, et al.
Publicado: (2022)

Patients presenting with stage IV uveal melanoma: Lessons learned
por: Garg, Gaurav, et al.
Publicado: (2022)

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
por: Gutiérrez, Lourdes, et al.
Publicado: (2021)

Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
por: Bakker, M., et al.
Publicado: (1995)

Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations
por: Li, Xing, et al.
Publicado: (2019)

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
por: Kanaoka, Kensuke, et al.
Publicado: (2023)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2021)

Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
por: Shi, Sheng-Bin, et al.
Publicado: (2013)

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
por: OZKAYA, SEVKET, et al.
Publicado: (2012)

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs
por: Kast, Richard E., et al.
Publicado: (2021)

Clinical profile of diabetic ketoacidosis in tertiary care hospital of Eastern Nepal
por: Maskey, Robin, et al.
Publicado: (2015)

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
por: Yang, James C.H., et al.
Publicado: (2020)

Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer
por: Li, Wenqian, et al.
Publicado: (2021)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
por: Takeda, Masayuki, et al.
Publicado: (2019)

Breast Milk Epidermal Growth Factor Confers Paracellular Calcium Absorption in the Infant Small Intestine
por: Burman, Andreanna, et al.
Publicado: (2023)

Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer
por: Fujita, A, et al.
Publicado: (2003)

A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus
por: Bang, Sun-Hwi, et al.
Publicado: (2012)

A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer
por: Sun, Manqiang, et al.
Publicado: (2020)

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
por: Ren, Fei, et al.
Publicado: (2022)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kcqhle7lnq1ookj8mrkj2j22aa